Literature DB >> 12527192

Expression, alternative splicing and haplotype analysis of transcribed testis specific protein (TSPY) genes.

Roswitha Krick1, Sibylle Jakubiczka, Joachim Arnemann.   

Abstract

Testis specific protein (TSPY) is a human Y-chromosome derived gene with numerous functional and non-functional copies. Specific expression patterns in testis and testicular tumors, as in prostate cancer samples and cell lines led to the postulation of a potential role in cell proliferation, supported by the presence of a suppressor of variegation, enhancer of zeste and Trithorax/nucleosome assembling protein (nucleosome assembly protein) domain in the mature protein. Expression studies have now identified two transcripts of variable length, termed TSPY-S and -L, which differ in their 3'-translated region due to alternative splicing, and in the quantitative level of transcripts, with TSPY-S being at least 3-4-fold more abundant. In immunoblot experiments on human testis and LNCaP protein extracts using an anti-peptide-antiserum against the TSPY-L specific C-terminus TSPY-L was characterized as a functional variant on the protein level. As there are at least three intragenic positions differing between various TSPY genes and thus defining certain haplotypes, the alternatively spliced TSPY transcripts were analysed for their haplotypes in order to link them to well defined TSPY loci. Surprisingly, no evidence of a G-G-18 haplotype was found for the TSPY-L transcript, while this haplotype makes up almost 50% of all TSPY-S transcripts. This excludes the corresponding TSPY-1 locus from alternative splicing. The only significant differences between the TSPY-1 locus and eight other loci were identified in the promotor region as revealed by detailed sequence comparisons. Thus one might speculate that the alternative splicing could be influenced by elements binding to the promotor region.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12527192     DOI: 10.1016/s0378-1119(02)01104-6

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  6 in total

1.  Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.

Authors:  Shihua Sun; Cynthia C T Sprenger; Robert L Vessella; Kathleen Haugk; Kathryn Soriano; Elahe A Mostaghel; Stephanie T Page; Ilsa M Coleman; Holly M Nguyen; Huiying Sun; Peter S Nelson; Stephen R Plymate
Journal:  J Clin Invest       Date:  2010-07-19       Impact factor: 14.808

2.  Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells.

Authors:  Ajay P Singh; Sangeeta Bafna; Kunal Chaudhary; Ganesh Venkatraman; Lynette Smith; James D Eudy; Sonny L Johansson; Ming-Fong Lin; Surinder K Batra
Journal:  Cancer Lett       Date:  2007-10-30       Impact factor: 8.679

3.  EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance.

Authors:  Yuexing Zhang; Douglas Linn; Zhenqiu Liu; Jonathan Melamed; Fabio Tavora; Charles Y Young; Angelika M Burger; Anne W Hamburger
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

4.  Epigenetic profile of the euchromatic region of human Y chromosome.

Authors:  Narendra Pratap Singh; Sri Ranganayaki Madabhushi; Surabhi Srivastava; R Senthilkumar; C Neeraja; Sanjeev Khosla; Rakesh K Mishra
Journal:  Nucleic Acids Res       Date:  2011-01-19       Impact factor: 16.971

5.  TSPY potentiates cell proliferation and tumorigenesis by promoting cell cycle progression in HeLa and NIH3T3 cells.

Authors:  Shane W Oram; Xing Xing Liu; Tin-Lap Lee; Wai-Yee Chan; Yun-Fai Chris Lau
Journal:  BMC Cancer       Date:  2006-06-09       Impact factor: 4.430

6.  TSPY1 suppresses USP7-mediated p53 function and promotes spermatogonial proliferation.

Authors:  Ying Shen; Wenling Tu; Yunqiang Liu; Xiling Yang; Qiang Dong; Bo Yang; Jinyan Xu; Yuanlong Yan; Xue Pei; Mohan Liu; Wenming Xu; Yuan Yang
Journal:  Cell Death Dis       Date:  2018-05-01       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.